Skip to main content
. 2024 Nov 12;16(11):1447. doi: 10.3390/pharmaceutics16111447

Figure 2.

Figure 2

Biological barriers that influence the pharmacokinetic characteristics of oligonucleotide-based drugs: (a)—nuclease degradation; (b)—reticuloendothelial system; (c)—blocking the lateral movement of oligonucleotide from the vessel lumen into the interstitial fluid; (d)—low efficiency of cell penetration; (e)—endo-lysosomal entrapment; (f)—blood–brain barrier.